• Home/
  • Health/
  • India Develops First Indigenous Hydroxyurea Oral Suspension To Combat Sickle Cell Disease At 1 Per cent Cost Of Global Price

Health

India Develops First Indigenous Hydroxyurea Oral Suspension To Combat Sickle Cell Disease At 1 Per cent Cost Of Global Price

Hydroxyurea Oral Suspension will be used for symptomatic management of sickle cell syndrome for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years

The pharmaceutical manufacturer Akums has the capacity to produce 2 crores bottles of Hydroxyurea Oral Suspension per month to tackle sickle cell disease

New Delhi: The pharmaceutical manufacturer Akums Drugs and Pharmaceuticals Limited has announced India’s first homegrown indigenous Hydroxyurea oral suspension for the treatment of sickle disease in children at 1 per cent cost of the global price. Union Minister Mansukh Mandaviya also congratulated Akums for developing a medicine to prevent sickle cell disease.

“Many congratulations to you for developing a medicine to prevent sickle cell disease. PM Modi launched the Sickle Cell Anemia Eradication Mission in 2023. This medicine will prove to be a boon, especially for our tribal sisters, brothers and children and we will soon free India from sickle cell,” Mr Mandaviya posted on X by tagging Akums.

Hydroxyurea Oral Suspension will be used for symptomatic management of sickle cell syndrome for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years.

Also Read, Over 1 Crore People Screened For Sickle Cell Disease Under National Sickle Cell Anaemia Elimination Mission

On the development of the sickle cell anaemia drug under Make in India, Akums MD Sanjeev Jain told ANI that the price of the medicine developed in India for sickle cell anaemia is 1 per cent of the global price.

Mr Jain said,

80 per cent population of this disease (sickle cell anaemia) is in Africa and India. We did some study and realised that we cannot eradicate this disease if its medicine is not available at a lower price. After some research, we have developed a medicine. The price is around 1 per cent (of the global price).

Mr Jain added,

Secondly, it is stable at room temperature. Earlier, the patients had to come to the hospital to take the medicine, but this medicine can be administered where they are. This medicine can be stored at a temperature of 25°C. It is suitable for children and adults. We worked on it for 2 years and we are ready to commercialise it. We are ready for the manufacturing also. We are hopeful that we will be able to provide this medicine for Rs 700-800.

Also Read, Highlights Of 2023: What Are The Interventions India Needs To Achieve Its Mission Of Eliminating Sickle Cell Anaemia By 2047?

Talking about the production of the medicine, Mr Jain said that the company has the capacity to produce 2 crores bottles per month.

Mr Jain said,

We are completely ready for the production (sickle cell anaemia drug). We have sent a commercial batch to the Drug Controller General of India (DCGI) for approval. We can produce 2 crore bottles per month.

The dosage of Hydroxyurea Oral Suspension is based on the patient’s body weight. The usual starting dose is 15mg/kg/day and the usual maintenance dose is between 20-25 mg/kg/day. The maximum dose is 35 mg/kg/day.

Officials from Akums told ANI,

Globally Hydroxyurea is available as a capsule and solution. Capsules can not be dose-calibrated and the solution needs to be stored at 2 to 8 degrees Celsius. Thus, there was a requirement for a formulation of Hydroxyurea that could be given based on body weight and is also stable at room temperature. This challenge was given to us by MoHFW and Dr V K Paul.

They further explained,

Our R&D team accepted the challenge and worked on multiple trials in two years. Finally, they succeeded and formulated a room-temperature stable oral suspension of Hydroxyurea. CDSCO (DCGI) asked us to do bioequivalence studies with a global brand. We completed BE studies and got approval from DCGI.

Also Read, Government Mulling Incentives For ASHA Workers To Mobilise Individuals For Sickle Cell Disease Screening

The officials added that the Indian Council of Medical Research (ICMR) will guide Akums to conduct the Post Marketing Surveillance (PMS) study.

The officials said,

Once the product is commercialized within a month, as per CDSCO requirement, Akums needs to do a Post Marketing Surveillance (PMS) study. Akums is honoured that we will be guided by ICMR to conduct PMS under their guidance.

The National Sickle Cell Anaemia Elimination Mission was launched by the Prime Minister on July 1, 2023, at Shahdol, Madhya Pradesh.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol have been working towards a clean and healthy India since 2014 via the Banega Swachh India initiative, which in its Season 10 is helmed by Campaign Ambassador Ayushmann Khurrana. The campaign aims to highlight the inter-dependency of humans and the environment, and of humans on one another with the focus on One Health, One Planet, One Future – Leaving No One Behind. It stresses on the need to take care of, and consider, everyone’s health in India – especially vulnerable communities – the LGBTQ populationindigenous people, India’s different tribes, ethnic and linguistic minorities, people with disabilities, migrants, geographically remote populations, gender and sexual minorities. In a world post COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign will continue to raise awareness on the same along with focussing on the importance of nutrition and healthcare for women and children, fight malnutrition, mental well-being, self-care, science and health, adolescent health & gender awareness. Along with the health of people, the campaign has realised the need to also take care of the health of the eco-system. Our environment is fragile due to human activity, which is not only over-exploiting available resources, but also generating immense pollution as a result of using and extracting those resources. The imbalance has also led to immense biodiversity loss that has caused one of the biggest threats to human survival – climate change. It has now been described as a “code red for humanity.” The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene. Banega Swasth India will also be taking forward the dream of Swasth Bharat, the campaign feels that only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and the country can become a Swasth or healthy India.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *